Clovis Oncology's (CLVS) Rubraca Significantly Improves PFS versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
Go back to Clovis Oncology's (CLVS) Rubraca Significantly Improves PFS versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA MutationCLOVIS ONCOLOGY (NASDAQ: CLVS) | Delayed: 0.08 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $0.08 | 52 Week High | $40.29 | |||
Open | $0.08 | 52 Week Low | $11.57 | |||
Day High | $0.08 | P/E | N/A | |||
Day Low | $0.08 | EPS | $-2.82 | |||
Volume | 1,385 |